July 24, 2018

Cannvas Appoints Dr. Daniel J. Bal, MD to Health and Innovation Advisory Board

Dr. Daniel J. Bal, MD Appointed to Cannvas’ Health and Innovation Advisory Board

Advisory Board to Guide Physician-Backed Content on Cannvas.me Platform

TORONTO, July 24, 2018 /CNW/ – Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE: MTEC; Frankfurt: 3CM), a leading business technology company within the cannabis space, is pleased to announce that the Company has appointed Dr. Daniel J. Bal, MD to its Health and Innovation Advisory Board. The Cannvas Health and Innovation Advisory Board oversees all content related to the Cannvas.me platform, which offers innovative tools and physician-backed content to the global cannabis community. The Cannvas.me platform enables users of all backgrounds and personas to fully understand the potential of cannabis through an unbiased educational platform designed specifically for the global medicinal and adult-use cannabis communities.

“I have been an advocate for the use of cannabis based treatments for healthcare and to improve the quality of life for certain patients for quite some time,” said Dr. Daniel Bal MD, Physician at Stamford Health. “There is a significant need for medical based information regarding the efficacy of cannabis to enable medical doctors to prescribe cannabis based medical treatment with confidence. I believe the Cannvas.me online platform can play a significant role in aggregating the data and information to organize and make this information to doctors on a broad scale. I look forward to taking an active role on the Cannvas Health and Innovation Advisory Board.”

“We are honoured to have Dr. Bal join our Health and Innovation Advisory Board as we prepare to launch Cannvas.me, our patient-centric platform featuring innovative tools & physician-backed content for audiences wishing to learn about healthcare through cannabis,” said Shawn Moniz, Chief Executive Officer, Cannvas MedTech Inc. “Dr. Bal is a widely respected and accomplished medical doctor specializing in Family Medicine, Wound Care, and an advocate of healthcare through cannabis. I look forward to working with Dr. Bal as we launch our platform that will assist doctorswith the prescribing of cannabis products to patients searching for real alternatives.”

Dr. Bal’s passion for patient care is driven by the relationships he builds with his patients and the ability to help them achieve a healthy lifestyle. He earned his medical degree from the American University of Antigua College of Medicine, Magna Cum Laude, and completed his residency at Stamford Hospital/Columbia University College of Physicians & Surgeons inFamily Medicine. He has also completed 3 years of General Surgery Residency both at Stamford Hospital and SUNY Downstate Medical Centerin Brooklyn, New York. He has been very active with research during his career and is a published author and competed in many research competitions and presentations.

During his residency, he had the privilege to provide care to the underserved community which further enhanced his training and skills. After residency Dr. Bal continued to be a part of the Stamford community and joined the Stamford Health Medical Group. He has a particular interest in wound care and will also be practicing at the Stamford Hospital Wound Care and Hyperbaric Center.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading business technology company within the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.